Quickvue at-home otc covid-19 test kit in Ghana

Product Description

Description: Quickvue at-home otc covid-19 test kit in Ghana lets you get rapid results in the privacy of your own home. Available over-the-counter, everything you need is in the package and taking the test is simple.

Ages 2 and up with adult collection

With or without symptoms when tested twice over two or three days with at least 24 to 36 hours between tests

How To Use:

Swabcollect a gentle nasal swab sample.

Swirlafter adding the swab to the solution tube.

Dipput the strip into the tube.

Read Resultsshows straightforward and easy-to-read results.

Collection Method/Analysis Location: At-Home Use

Sample Type: Direct Anterior Nasal Swab

Diagnostic Target: Antigen

Time to Results: 10 minutes

Age Requirements: 2 years and older (aged 13 years and younger with adult-collected samples)

Quickvue at-home otc covid-19 test kit in Ghana

Swabs

Test Strips

Prefilled Tubes

Tube Holder

Instruction Sheet

Fact Sheet for Individuals

Additional Resources:

FDA EUA

HCP Fact Sheet

Patient Fact Sheet

Instructions for Use

Video Demonstration

Expiration Date: 24 months from date of manufacture

Quickvue at-home otc covid-19 test kit in Ghana

Storage Requirements: Room Temperature (59 to 86 F)

Per the CDC: For the best results, collect and handle the sample according to the manufacturers instructions. If you dont collect the sample as directed, your test results may be incorrect. Once collected, send the sample to a testing facility or use the sample as described in the manufacturers instructions to complete the at-home test.

This test has not been FDA cleared or approved but has been authorized by FDA under an EUA for use by authorized laboratories; This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.